EA201070722A1 - Пептидомиметики с активностью антагонистов глюкагона и агонистов glp-1 - Google Patents

Пептидомиметики с активностью антагонистов глюкагона и агонистов glp-1

Info

Publication number
EA201070722A1
EA201070722A1 EA201070722A EA201070722A EA201070722A1 EA 201070722 A1 EA201070722 A1 EA 201070722A1 EA 201070722 A EA201070722 A EA 201070722A EA 201070722 A EA201070722 A EA 201070722A EA 201070722 A1 EA201070722 A1 EA 201070722A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glp
activity
peptidomymetics
agonists
glucagon antagonists
Prior art date
Application number
EA201070722A
Other languages
English (en)
Other versions
EA018000B1 (ru
Inventor
Раджеш Х. Бахекар
Мукул Р. Джаин
Панкадж Раманбхай Пател
Original Assignee
Кадила Хелзкэр Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кадила Хелзкэр Лимитед filed Critical Кадила Хелзкэр Лимитед
Publication of EA201070722A1 publication Critical patent/EA201070722A1/ru
Publication of EA018000B1 publication Critical patent/EA018000B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Настоящее изобретение относится к новым пептидомиметикам формулы (I), которые преимущественно действуют как стимуляторы глюкозозависимой секреции инсулина. Кроме того, выявлено, что эти пептидомиметики наряду с активностью агониста рецептора GLP-1 демонстрируют активность антагониста рецептора глюкагона.
EA201070722A 2007-12-11 2008-12-10 Пептидомиметики с активностью антагонистов глюкагона и агонистов glp-1 EA018000B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2420MU2007 2007-12-11
IN1696MU2008 2008-08-11
PCT/IN2008/000831 WO2009125424A2 (en) 2007-12-11 2008-12-10 Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities

Publications (2)

Publication Number Publication Date
EA201070722A1 true EA201070722A1 (ru) 2010-12-30
EA018000B1 EA018000B1 (ru) 2013-04-30

Family

ID=41066190

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070722A EA018000B1 (ru) 2007-12-11 2008-12-10 Пептидомиметики с активностью антагонистов глюкагона и агонистов glp-1

Country Status (15)

Country Link
US (1) US8883963B2 (ru)
EP (1) EP2231701B1 (ru)
JP (1) JP5270687B2 (ru)
KR (1) KR101277560B1 (ru)
AT (1) ATE554098T1 (ru)
CA (1) CA2707448C (ru)
DK (1) DK2231701T3 (ru)
EA (1) EA018000B1 (ru)
ES (1) ES2382579T3 (ru)
IL (1) IL206252A0 (ru)
MX (1) MX2010006287A (ru)
NI (1) NI201000095A (ru)
PT (1) PT2231701E (ru)
WO (1) WO2009125424A2 (ru)
ZA (1) ZA201003804B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2491054A2 (en) 2009-10-22 2012-08-29 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2822017C (en) 2010-12-23 2015-04-07 Pfizer Inc. Glucagon receptor modulators
EP2673260B1 (en) 2011-02-08 2016-08-17 Pfizer Inc Glucagon receptor modulator
CA2841237C (en) 2011-07-22 2016-05-10 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
KR20160098406A (ko) * 2013-12-13 2016-08-18 메디뮨 리미티드 프로테아제 내성 펩티드
US10189884B2 (en) 2014-04-28 2019-01-29 The Trustees Of The University Of Pennsylvania Thioamide-modified peptides and uses thereof
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036711A1 (es) * 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
PL377687A1 (pl) * 2001-10-18 2006-02-06 Bristol-Myers Squibb Company Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą
EP1891106A2 (en) * 2005-05-05 2008-02-27 Cadila Healthcare Ltd. Novel compounds as glp-i agonists
CA2607566A1 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
US20070238669A1 (en) 2006-01-11 2007-10-11 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
US20100022457A1 (en) * 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
AU2007323035B2 (en) 2006-10-03 2011-11-24 Cadila Healthcare Limited Antidiabetic compounds

Also Published As

Publication number Publication date
EA018000B1 (ru) 2013-04-30
JP5270687B2 (ja) 2013-08-21
MX2010006287A (es) 2010-10-26
US20120021972A1 (en) 2012-01-26
WO2009125424A3 (en) 2009-12-23
KR101277560B1 (ko) 2013-06-25
KR20100101110A (ko) 2010-09-16
PT2231701E (pt) 2012-05-28
IL206252A0 (en) 2010-12-30
ES2382579T3 (es) 2012-06-11
WO2009125424A2 (en) 2009-10-15
CA2707448C (en) 2014-10-14
US8883963B2 (en) 2014-11-11
DK2231701T3 (da) 2012-05-21
ZA201003804B (en) 2011-01-26
JP2011506428A (ja) 2011-03-03
ATE554098T1 (de) 2012-05-15
EP2231701B1 (en) 2012-04-18
EP2231701A2 (en) 2010-09-29
CA2707448A1 (en) 2009-10-15
NI201000095A (es) 2011-05-04

Similar Documents

Publication Publication Date Title
EA201070722A1 (ru) Пептидомиметики с активностью антагонистов глюкагона и агонистов glp-1
MX2009003400A (es) Compuestos antidiabeticos.
MX2018005129A (es) Agonistas del receptor de glucagon.
CO6400136A2 (es) Agosnistas del receptor gpr120 y usos de los mismos
EA201391764A1 (ru) Агонисты рецептора glp-1/глюкагона длительного действия
ECSP11010989A (es) Agonistas del receptor gpr120 de arilo y usos de los mismos
EA201891360A1 (ru) Тройной агонист рецепторов глюкагона/glp-1/gip
EA202090392A3 (ru) Соединения-коагонисты гип и гпп-1
EA201690629A1 (ru) Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201390182A1 (ru) Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
AR099977A1 (es) Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4
EA201170305A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
EA201590065A1 (ru) Аналоги глюкагона, проявляющие активность на рецепторе gip
PE20151239A1 (es) Derivados de exendina-4 funcionalizada
CL2011000978A1 (es) Compuestos derivados de fenil-amida o piridil-amida, agonistas de gpbar1; proceso de preparacion; composicion farmaceutica; y su uso en diabetes, isquemia, obesidad, dislipidemia, entre otras.
EA201690660A1 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
EP3922260A3 (en) Insulin receptor partial agonists and glp-1 analogues
CR10694A (es) Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y procedimientos de uso
EA201170302A1 (ru) Процессированные аналоги глюкозозависимого инсулинотропного полипетида
CL2010000667A1 (es) Compuestos derivados de ciclohexil-piperazinil-metanona, antagonistas y/o agonistas inverso h3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de la obesidad, diabetes tipo ii y dislipidemia (sol. div. 60-07).
EA201101138A1 (ru) Соединение с конденсированным кольцом и его применение
PE20151871A1 (es) Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos
CL2011000071A1 (es) Compuestos derivados de oxazolopirimidinas, antagonistas del receptor edg-1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades cardiovasculares, trombosis, aterosclerosis, hipertension, diabetes, enfermedades renales, respiratorias, inflamatorias y autoinmunes, entre otras.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU